VEGF as an activity marker in rheumatoid arthritis. (June 2010)

• Record Type: Journal Article
• Authors: Szekanecz, Zoltán; Koch, Alisa E
• Is Part Of: International journal of clinical rheumatology. Volume 5:Number 3(2010)
• Page Start: 287
• Page End: 289
• Publication Date: 2010-06
• Subjects: angiogenesis -- rheumatoid arthritis -- vascular endothelial growth factor; Rheumatology -- Periodicals; 616.723005
• DOI: 10.2217/ijr.10.24
• Languages: English
• ISSNs: 1758-4272

Abstract

Evaluation of: Ozgonenel L, Cetin E, Tutun S, Tonbaklar P, Aral H, Guvenen G: The relation of serum vascular endothelial growth factor level with disease duration and activity in patients with rheumatoid arthritis. Clin. Rheumatol. 29(5), 473–477 (2010). VEGF is a crucial mediator of angiogenesis. It has been implicated in neovascularization associated with cancer metastasis, as well as arthritis. Hypoxia present in the inflamed joints, as well as hypoxia-inducible factors mediate VEGF production that leads to endothelial cell prolifertaion and angiogenesis. Serum VEGF levels have been associated with the clinical activity of rheumatoid arthritis. VEGF targeting using anti-VEGF and anti-VEGF receptor antibodies, small molecule inhibitors of VEGF signalling has been utilized in oncology and, very recently, in arthritis therapy.